Related references
Note: Only part of the references are listed.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
V. D'Amato et al.
BRITISH JOURNAL OF CANCER (2014)
Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Gianmaria Liccardi et al.
CLINICAL CANCER RESEARCH (2014)
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
Xiaoyong Fu et al.
BREAST (2013)
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Amanda Herzog et al.
CLINICAL CANCER RESEARCH (2013)
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines
Annett Mueller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
Christopher R. Zito et al.
PLOS ONE (2012)
The role of EGFR-targeting strategies in the treatment of head and neck cancer
Didier Dequanter et al.
ONCOTARGETS AND THERAPY (2012)
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts
Alexandre Bozec et al.
ORAL ONCOLOGY (2011)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model
A. Bozec et al.
ANNALS OF ONCOLOGY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Dysregulated molecular networks in head and neck carcinogenesis
Alfredo A. Molinolo et al.
ORAL ONCOLOGY (2009)
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data
Cristiana Lo Nigro et al.
BJU INTERNATIONAL (2008)
Chemoradiotherapy in head and neck squarnous cell carcinoma: Focus on targeted therapies
A. Bozec et al.
CANCER RADIOTHERAPIE (2008)
EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences
Olivier Dassonville et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications
Michel Zimmermann et al.
RADIATION ONCOLOGY (2006)
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck
P Amornphimoltham et al.
CANCER RESEARCH (2005)
Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma
JMG Pedrero et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion
A Yacoub et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2001)
Akt regulates cell survival and apoptosis at a postmitochondrial level
HL Zhou et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
